CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
CorMedix Therapeutics (Nasdaq: CRMD) announced that Chairman and CEO Joseph Todisco will deliver a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Monday, January 12, 2026 at 4:30pm PST in presentation format and will be available via webcast.
Positive
- None.
Negative
- None.
News Market Reaction – CRMD
In the Jan 9 session, CRMD gained 1.60%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.5% during that session. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Clinical data update | Positive | +4.1% | Interim real-world DefenCath data showing large CRBSI and hospitalization reductions. |
| Nov 12 | Strategic investment | Neutral | +2.1% | Talphera financing led by CorMedix and progress on NEPHRO CRRT study timelines. |
| Nov 12 | Earnings/guidance | Positive | +2.1% | Profitable Q3 with higher DefenCath use, Melinta contribution, and raised FY guidance. |
| Oct 31 | Earnings preview | Neutral | -4.2% | Announcement of upcoming Q3 results call and pipeline/commercialization overview. |
| Oct 23 | Product designation | Positive | +1.0% | Vizient Innovative Technology designation for DefenCath highlighting clinical benefit. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CRMD news has generally been positive with predominantly favorable price reactions, suggesting the stock has tended to respond constructively to operational and clinical updates.
Over the last several months, CorMedix reported multiple positive developments. Q3 2025 results showed strong profitability with net income of $108.6M and raised FY 2025 revenue and EBITDA guidance, supported by the Melinta acquisition and growing DefenCath utilization. DefenCath real‑world data in ~7,000 patients showed large reductions in infections and hospitalizations. Vizient granted DefenCath an Innovative Technology designation, while ongoing Phase III programs target further label and portfolio expansion. Today’s conference presentation fits into a pattern of active investor communication following these milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY HEIGHTS, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that Joseph Todisco, Chairman and CEO of CorMedix Therapeutics, will present a corporate overview at the 44th annual J.P. Morgan Healthcare Conference. The presentation is scheduled to take place on Monday, January 12, 2026 at 4:30pm PST.
44th Annual J.P. Morgan Healthcare Conference
| Date: | Monday, January 12, 2026 |
| Time: | 4:30pm PST |
| Format: | Presentation |
| Webcast: | Link |
About CorMedix
CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. CorMedix is commercializing DefenCath® (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter. Following its August 2025 acquisition of Melinta Therapeutics LLC, CorMedix is also commercializing a portfolio of anti-infective products, including MINOCIN® (minocycline) for Injection, REZZAYO® (rezafungin for injection), VABOMERE® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA® (delafloxacin), and KIMYRSA® (oritavancin), as well as TOPROL-XL® (metoprolol succinate).
CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition (TPN) and Pediatric Hemodialysis populations and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. REZZAYO is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of IFD in adult patients undergoing allogeneic BMT. Topline results of the Phase III study for REZZAYO are expected in Q2 2026. For more information visit: www.cormedix.com or www.melinta.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
